JPH0250894B2 - - Google Patents

Info

Publication number
JPH0250894B2
JPH0250894B2 JP56008493A JP849381A JPH0250894B2 JP H0250894 B2 JPH0250894 B2 JP H0250894B2 JP 56008493 A JP56008493 A JP 56008493A JP 849381 A JP849381 A JP 849381A JP H0250894 B2 JPH0250894 B2 JP H0250894B2
Authority
JP
Japan
Prior art keywords
group
mmol
extracted
reduced pressure
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP56008493A
Other languages
Japanese (ja)
Other versions
JPS57122041A (en
Inventor
Hajime Fujimura
Mikio Hori
Toshio Tatsuoka
Mitsuto Okitsu
Kayoko Imao
Minoru Morita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suntory Ltd
Original Assignee
Suntory Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Ltd filed Critical Suntory Ltd
Priority to JP56008493A priority Critical patent/JPS57122041A/en
Publication of JPS57122041A publication Critical patent/JPS57122041A/en
Priority to JP2073923A priority patent/JPH02275871A/en
Publication of JPH0250894B2 publication Critical patent/JPH0250894B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Description

【発明の詳細な説明】 本発明は下記一般式()で表わされるフエニ
ルシクロヘキサン誘導体に関する。 (式中、 R1は水素原子、水酸基またはメトキシ基のい
ずれか、 R2はN,N―ジメチルアミノエチル基または
N,N―ジメチルカルバモイルメチル基のいずれ
か、 R3はメチルカルボニルアミノ基、エチルカル
ボニルオキシ基、ジメチルアミノメチルカルボニ
ルオキシ基、ジメルアミノエトキシ基またはピペ
リジノメチルカルボニルオキシ基のいずれかを示
す。) 本発明化合物は血小板凝集の抑制作用、摘出腸
管収縮抑制作用または消炎鎮痛作用を示し医薬と
して有用なものであり、次の一般的製法によつて
製造することができる。 下記一般式()で表わされる2―フエニルシ
クロヘキサン類または相当する2―フエニルシク
ロヘキサノール類を出発原料とし、 (但しR1が水酸基の場合はベンジルその他の保
護基を導入し、最後に該保護基を取去ることが好
ましい。)公知の方法でR2及び導入して本発明化
合物を得ることができる。 参考例 2―N,N―ジメチルカルバモイルメチル―2
―フエニルシクロヘキサノールの製造 2―N,N―ジメチルカルバモイルメチル―2
―フエニルシクロヘキサノン2.59gのメタノール
50ml溶液に氷冷下水素化ホウ酸ナトリウム500mg
を加え、室温にて2時間攪拌後反応液を減圧濃縮
し水で希釈し、エーテルで3回抽出。抽出液を水
洗し乾燥後減圧濃出することにより2.6g(収率
100%)の結晶を得た。この結晶をベンゼン―ヘ
キサン混合溶媒より再結晶をし標記化合物の純品
を得た。 融点112―113℃ IRνcm-1:3150(OH),1600(CO) NMR:2.50,2.69(―N―CH3),4.05(―C
―OH) 実施例 1 1―N,N―ジメチルアミノエチル―2―プロ
ピオニルオキシ―1―フエニルシクロヘキサン
の製造 2―ジメチルアミノエチル―2―フエニルシク
ロヘキサノール2.00g(8.10ミリモル)を塩化メ
チレン30mlに溶かし0.774ml(1.1当量)のプロピ
オニルクロリドおよびび炭酸ナトリウム0.945g
(1.1当量)を加え2時間加熱環流する。さらに
0.704ml(1当量)のプロピオニルクロリドと炭
酸ナトリウム0.859g(1当量)を加え室温で16
時間攪拌する。反応液を水にあけ、10%アンモニ
ア液でアルカリ性にしクロロホルムで抽出する。
クロロホルム層1を2規定塩酸水溶液で抽出す
る。水層を10%アンモニア液でアルカリ性にしク
ロロホルムで抽出する。クロロホルム層を乾燥し
溶媒留去して油状物を得る。クロロホルム1を2
規定塩酸水溶液で抽出した際のクロロホルム層を
5%アンモニア液で洗浄し溶媒留去しエーテルに
溶解する。2規定塩酸水溶液で抽出し水層を10%
アンモニア水溶液でアルカリ性にした後クロロホ
ルムで抽出する。クロロホルム層を乾燥して溶媒
留去して油状物を得る。油状物を合わせて標記化
合物の塩酸塩2.08g(収率72.5%)を得る。 IRcm-1:1740(CO) NMR:0.71(―CO―CH2―C 3),2.02(―N
(C 32),5.18( ―CH――O― ‐),7.16(フエ
ニル). 実施例 2 1―N,N―ジメチルカルバモイルメチル―2
―N,N―ジメチルカルバモイルオキシ―1―
フエニルシクロヘキサンの製造 1.44g(5.53ミリモル)の2―N,N―ジメチ
ルカルバモイルメチル―2―フエニルシクロヘキ
サノール(参考例参照)を無水塩化メチレンに溶
解し、無水炭酸ナトリウム590mg(5.54ミリモル)
およびクロルアセチルクロリド626mg(5.53ミリ
モル)を加え2時間加熱環流した。冷却後反応液
を水に注ぎ、塩化メチレンで抽出(2回)した。
抽出液を無水硫酸マグネシウムで乾燥後減圧濃縮
すると1.86gの該シクロヘキサノールのクロルア
セテートが得られた(収率定量的)。引き続き上
記化合物をベンゼンに溶解し封管中に入れ、ジメ
チルアミン10等量を含んだベンゼン溶液を加え
110で4時間加熱した。取り出したベンゼン溶液
を2回水洗し乾燥した後、減圧濃縮することによ
り1.35gの標記化合物を得た(収率71%)。 NMR:2.27,2.67(―CO―N(CH32),2.13
(―N(CH32),2.90(―CO―CH2―N),
5.65( ―CH――O―CO ‐) 塩酸塩とした後エタノール―エーテル混合溶媒
より再結晶し純品を得た。 融点77―79℃ 実施例 3 1―N,N―ジメチルアミノエチル―2―N,
N―ジメチルカルバモイルオキシ―1―フエニ
ルシクロヘキサンの製造 2―ジメチルアミノエチル―2―フエニルシク
ロヘキサノール4.32g(17.5ミリモル)を無水ベ
ンゼン120mlに溶解し、窒素気流下5℃でクロル
アセチルクロリド1.39ml(1当量)を滴下する。
これを5℃で40分攪拌する。反応液を30℃で溶媒
留去すると該シクロヘキサノールのクロルアセテ
ートの油状物を得る。これを少量のエタノールで
封管に流し込みジメチルアミンのエタノール溶液
(ジメチルアミン約12.0gを含む15.2当量)100ml
を加え、40―50℃で1時間加熱する。反応液を溶
媒留去し水に懸濁してエーテルで抽出する。エー
テル層を2規定塩酸水溶液で抽出し水層を10%ア
ンモニア水でアルカリ性にし塩化メチレンで抽出
する。塩化メチレン層を乾燥し溶媒留去すると油
状物3.64gを得る。油状物を塩酸塩としエタノー
ル―エーテルより再結晶すると標記化合物の塩酸
塩結晶1.60g(収率24.7%)を得る。 融点233―239℃ IRcm-1:1740 NMR:2.07(―N(C 32), 5.26( ―CH――O― ‐),7.23(フエニル) 実施例 4 2―N―アセチルアミノ―1―N,N―ジメチ
ルアミノエチル―1―フエニルシクロヘキサン
の製造 2.12g(8.6ミリモル)の2―ジメチルアミノ
エチル―2―フエニルシクロヘキサノンを20mlの
80%エタノール水溶液に溶解し、1.21g(17.3ミ
リモル)のヒドロキシルアミン塩酸塩および1.42
(17.3ミリモル)の無水酢酸ナトリウムを加え2
時間加熱還流後減圧濃縮する。残留物を水で希釈
しクロロホルムで3回抽出し抽出液を無水硫酸マ
グネシウムで乾燥する。抽出液を過後減圧濃縮
すると2.25gの粗生成物が得られる。 IRνcm-1:1700(C=N),3300(OH) 本粗生成物を無水エーテル50mlに溶解し、この
エーテル溶液を別に調製した過剰の水素化アルミ
ニウムリチウを含むエーテル溶液に加え、混合物
を2時間加熱還流する。冷却後反応混合物を30%
カ性ソーダ水溶液で分解し、エーテルで3回抽
出、抽出液を飽和食塩水で洗浄した後無水硫酸マ
グネシウムで乾燥する。乾燥した抽出液を過後
減圧濃縮すると2.12gの粗生成物が得られる。 IRνcm-1:3500,1640(NH2) 上記粗生成物をピリジン20mlに溶解し無水酢酸
10mlを加え室温で16時間攪拌する。反応溶液を減
圧濃縮し残留物を塩化メチレンに溶解し2規定塩
酸で抽出後、5%アンモニア水で塩基性にもどし
塩化メチレンで3回再抽出する。乾燥後減圧濃縮
すると1.27gの標記化合物が得られる(収率60
%)。 IRνcm-1:1640(CO),3300(NH) NMR:1.60(―COCH3),2.10(―Z(CH32),
4.46( ―CH――NH― ‐),5.95(―NH―CO―) 上記化合物を塩酸塩にした後エタノール―エー
テル混合溶媒により再結晶して純品を得た。 融点127―130℃ 実施例 5 1―N,N―ジメチルカルバモイルメチル―2
―N,N―ジメチルカルバモイルオキシ―1―
(3―メトキシフエニル)シクロヘキサンの製
造 2.1g(18.7ミリモル)のカリウムt―ブトキ
シドを無水ジメチルスルホキシドに溶解し、3.19
g(15.6ミリモル)の2―(3―メトキシ)フエ
ニルシクロヘキサノンを加え室温で30分攪拌す
る。次にN,N―ジメチルクロルアセトアミド
2.27g(18.7ミリモル)のジメチルスルホキシド
溶液を氷冷下に滴下し、混合物を100℃で2時間
加熱攪拌する。冷却後反応液を水に注ぎクロロホ
ルムで3回抽出し、水洗した後無水硫酸マグネシ
ウムで乾燥する。抽出液を過後減圧濃縮すると
5.86gの粗生成物が得られる。このものを300g
のシリカゲルを用いカラムクロマトグラフイーを
行うことにより1.75gの2―N,N―ジメチルカ
ルバモイルメチル―2―(3―メトキシ)フエニ
ルシクロヘキサノン純品を得た(収率39%)。 IRνcm-1:1700(CO),1640(N―CO) NMR:2.65,2.79(―N(CH32), 2.76( ―CH2―CON― ‐ ),3.77(―OCH3) 1.75gの前記化合物をメタノールに溶解し氷冷
下水素化ホウ素ナトリウムを加え室温で2時間攪
拌後、反応液を濃縮する。残渣に水を加え生成物
をエーテルで3回抽出し水洗した後、無水硫酸マ
グネシウムで乾燥する。抽出液を過後減圧濃縮
すると1.25gの2―N,N―ジメチルカルバモイ
ルメチル―2―(3―メトキシ)フエニルシクロ
ヘキサノールが得れる(収率71%)。 IRνcm-1:3400(OH),1605(N―CO) NMR:2.60,2.78(N(CH32),3.78(O―
CH3),2.70( ―CH―2―CON― ‐ ), 4.1( ―CH――OH ‐) 1.25g(4.3ミリモル)の前記化合物を塩化メ
チレンに溶解し、456mg(4.3ミリモル)の炭酸ソ
ーダおよび456mg(4.6ミリモル)のクロルアセチ
ルクロリドを加え、混合物を2時間加熱還流す
る。冷却後反応混合物を水に注ぎ分離する。水層
は塩化メチレンで2回抽出し、先の塩化メチレン
層共に無水硫酸マグネシウムで乾燥する。過後
減圧濃縮すると1.52gの2―N,N―ジメチルカ
ルバモイルメチル―2―(3―メトキシ)フエニ
ルシクロヘキサノールクロルアセテートが得られ
る(収率96%)。 1.52g(4.3ミリモル)の前記化合物のジメチ
ルホルムアミド溶液にジメチルアミン4.2gを含
んだジメチルホルムアミド溶液を加え、封管中で
100℃で4時間加熱する。冷却後内容物をフラス
コに注ぎ減圧濃縮する。残渣に2規定塩酸および
エーテルを加え分離するる。水層に10%アンモニ
ア水を加え塩寄性にした後、塩化メチレンで3回
抽出し無水硫酸マグネシウムで乾燥する。過後
減圧濃縮すると1.35gの標記化合物が得られる
(収率87%)。 NMR:2.15(―N(CH32),2.30,2.70(―
CON(CH32,2.85( ―CH2―CON― ‐ ),2.95
( ―CO―CH―2―N― ‐ ),3.75(―OCH3),
5.65( ―CH――O―CO ‐) 塩酸塩とした後エタノール―エーテル混合液よ
り再結晶して純品を得た。 融点191―192℃ 元素分析 分子式C21H32N2O4・HClとして 計算値 C:61.08;H:8.06;N:6.78 実測値 C:60.99;H:8.14;N:6.78 実施例 6 1―N,N―ジメチルカルバモイルメチル―2
―N,N―ジメチルカルバモイルオキシ―1―
(3―ヒドロキシフエニル)シクロヘキサンの
製造 無水ジメチルスルホキシド11mlにカリウムt―
ブトキシド1.47g(13.1ミリモル)を少量ずつ加
え、次に2―(3―ベンジルオシ)フエニルシク
ロヘキサノン3.05g(10.9ミリモル)のジメチル
スルホキシド溶液を加え、室温にて30分攪拌した
後2―クロロ―N,N―ジメチルアセトアミド
1.59g(13.1ミリモル)を加える。次に混合物を
100℃の油浴上で2時間加熱攪拌する。冷却後反
応混合物を水に注ぎ塩化メチレンで抽出する(3
回)。抽出液を水洗後無水硫酸マグネシウムで乾
燥し、過後減圧濃縮すると4.2gの2―N,N
―ジメチルカルバモイルメチル―2―(3―ベン
ジルオキシ)フエニルシクロヘキサノンが得られ
る。 NMR:2.59,2.75(―N(CH32), 2.70( ―CH2―CO―N― ‐ ),4.90(―O―C 2
―フエニル) 前記化合物4.1g(10ミリモル)を50mlのメタ
ノールに溶解し、等モルの水素化ホウ素ナトリウ
ム410mgを加え室温で1時間攪拌する。濃縮後水
で希釈し塩化メチレンで抽出し抽出液を水で洗浄
後、無水硫酸マグネシウムで乾燥する。過後減
圧濃縮すると3.51gの粗生成物が得られる。本品
をシリカゲルのカラムクロマトグラフイーで分離
精製し2.0gの2―N,N―ジメチルカルバモイ
ルメチル―2―(3―ベンジルオキシ)フエニル
シクロヘキサノールを得た(収率2段階で50%)。 NMR:2.55,2.72(―N(CH32), 2.65( ―CH2―CON― ‐ ),4.05( ―CH――OH ‐),
5.04(―O―CH―2―フエニル) 前記化合物1.5g(4.08ミリモル)を塩化メチ
レン50mlに溶解し、等モルの炭酸ソーダ(435mg)
およびクロルアセチルクロリド(461mg)を加え
1時間半加熱還流する。冷却後反応液を水に注ぎ
塩化メチレンで抽出し、抽出液を無水硫酸マグネ
シウムで乾燥する。過後減圧濃縮すると1.47g
の抽状の2―N,N―ジメチルカルバモイルメチ
ル―2―(3―ベンジルオキシ)フエニルシクロ
ヘキサノールクロルアセテートが得られる(収率
81%)。 IRνcm-1:1620(―CO―N),1730(―COO―) NMR:2.60,2.75(―N(CH32),3.76(Cl―C
2―COO),5.01(―O―C 2―フエニル),
5.59( ―CH――OCO ‐) 前記化合物1.36gのジメチルホルムアミド溶液
にジメチルアミン20等量を含んだジメチルホルム
アミドを加え、封管中で100〜110℃で4時間加熱
する。減圧濃縮すると、1.22gの2―N,N―ジ
メチルカルバモイルメチル―2―(3―ベンジル
オキシ)フエニルシクロヘキサノール,N,N―
ジメチルアミノアセテートが得られる(収率88
%)。 IRcm-1:1620(―N―CO),1720(―O―CO―) NMR:2.25,2.67(―CO―N(CH32),2.15
(―CH2―N(C 32), 2.60( ―CH2―CO―N― ‐ ), 2.90( ―CO―CH2―N― ‐ ),5.00(―O―CH2
―フエニル) 1.21gの前記化合物を塩酸塩とした後エタノー
ルに溶解し、10%パラジウムカーボンを1.2g加
え水素気流下で5時間攪拌する。過後濃縮し残
渣を2規定塩酸とエーテルで分画する。塩酸層を
10%アンモニア水で塩基性にした後、クロロホル
ムで抽出し無水硫酸マグネシウムで乾燥する。
過後減圧濃縮すると820mgの標記化合物が得られ
る(収率85%)。 IRcm-1:3300(―OH),1720(―COO),1640
(―N―CO) NMR:2.20(―N(CH32),2.30,2.72(―CO
―N(CH32),2.55( ―CH―2―CON― ‐ ),
3.01( ―CO―CH―2―N― ‐ ), 5.62( ―CH――O― ‐) 上記化合物を塩酸塩とした後エタノール―エー
テル混合溶媒より再結晶して純品を得る。 融点 144―145℃ 元素分析 分子式C20H29N2O4として 計算値 C:66.27;H:8.34;N:7.73 実測値 C:66.50;H:8.40;N:7.73 実施例 7 1―N,N―ジメチルカルバモイルメチル―1
―(3―メトキシフエニル)―2―ピペリジノ
メチルカルボニルオキシシクロヘキサンの製造 1.14gの2―N,N―ジメチルアセトアミド―
2―(3―メトキシ)フエニルシクロヘキサノー
ルクロルアセテートをジメチルホルムアミドに溶
解し、10倍当量のピペリジンを加え100℃で4時
間加熱攪拌する。反応液を濃縮し2規定塩酸とエ
ーテルを加え分離する。水層に10%アンモニア水
を加え塩基性とした後、塩化メチレンで3回抽出
し無水硫酸マグネシウムで乾燥する。過後減圧
濃縮すると1.19gの油状の標記化合物が得られる
(収率97%)。 IRcm-1:1640(―N―CO),1730(―OCOCH2) NMR:2.30,2.70(CON(CH32),3.73(―
OCH3),5.60( ―CH――OCO ‐) 本品を塩酸塩として調製した。 元素分析 分子式C24H3N2O4として 計算値 C:69.20;H:8.71;N:6.73 実測値 C:68.73;H:8.86;N:6.69 実施例 8 2―N,N―ジメチルアミノエチルオキシ―1
―N,N―ジメチルカルバモイルメチル―1―
(3―メトキシフエニル)シクロヘキサンの製
造 2―N,N―ジメチルアセトアミド―2―(3
―メトキシ)フエニルシクロヘキサノール700mg
(2.4ミリモル)を無水ジメチルホルムアミドに溶
解し、窒素気流下水素化ナトリウムを加え室温に
て30分間攪拌する。続いてジメチルアミノエチル
クロリドを滴下し室温で1時間攪拌した後、50℃
で更に2時間加熱攪拌する。冷却後水に注ぎ塩化
メチレンで3回抽出した後2規定塩酸で逆抽出す
る。水層を10%のアンモニア水で塩基性にした
後、塩化メチレンで再抽出し無水硫酸マグネシウ
ムで乾燥する。過後減圧濃縮すると260mgの油
状の標記化合物が得られる(収率31%)。 IRcm-1:1620(―CON―) NMR:2.20(―N(CH32),2.35,2.70(―
CON(CH32),2.80( ―CH―2―CO―N― ‐ ),
3.0―3.6( ―O―CH2―CH2―N― ‐ ),3.73(―
OCH3),4.05( ―NH――O― ‐) 元素分析 分子式C12H34N2O3として 計算値 C:69.58;H:9.45;N:7.73 実測値 C:69.56;H:9.46;N:7.50 次に本発明化合物の薬理作用について述べる。 1 血小板凝集抑制作用 ウサギの耳動脈よりクエン酸ナトリウムを抗
凝固剤として用いて採血する。遠心分画によつ
て多血小板漿(PRP)と乏血小板血漿(PPP)
を得る。血小板数を40万mm3に調整した
PRP250μをアグロメーター(理化電機製
HUM式)のキユベツトに入れ、37℃でインキ
ユベートしながら1ミリモルの塩化カルシウム
を加える。1分後に被検化合物を適量加える。
更に1分後に凝集剤としてアデノシン二リン酸
(ADP)10μモルまたはコラーゲン38μg/mlま
たはアラキドン酸0.3ミリモルを加え、光の透
過率の変化をアナログメーターで測定する。凝
集作用は対照の最大凝集を100としてその抑制
率を求め凝集を50%抑制する試料濃度(IC50μ
g/ml)で比較する。その結果を次表に示す。 【表】 2 摘出腸管収縮抑制作用 体重400〜700gの雄性モルモツトから約2cm
の回腸を摘出し、マグヌス法により試験を行な
つた。回腸をマグヌス槽(タイロード液38℃空
気通気)中に懸垂し、その収縮反応を等張性ト
ランスジユーサーを介して記録した。腸管の長
さが一定に保たれるようにセツトした後、カル
バコールまたはヒスタミンを1×10-10〜1×
10-5g/mlの濃縮範囲内で、累積的に添加し収
縮物による用量―反応曲線を求めた後、洗浄し
被検化合物存在下に収縮物による用量―反応曲
線を求め、この反応の違いから拮抗作用
PD2′を算出した。その結果を次に示す。 化合物 PD2′ 実施例1 4.59 〃 2 4.06 〃 3 4.35 対照パパベリン 5.43 3 鎮痛作用 a 酢酸ライシング法(1) 体重15〜20gのddY系雄マウスを1群5匹
として、被検化合物経口投与30分後に0.6%
酢酸0.1ml/10gをマウスの腹腔内に注射し、
5〜10分後に生ずるライシイングの回数を数
えライシングの回数が10回未満の場合を鎮痛
効果陽性と判定した。その結果を次に示す。 化合物 ED50mg/Kg 実施例1 32 〃 2 21 〃 3 65 〃 4 53 〃 5 3.9 b 酢酸ライシイング法(2) 体重16〜20gのddY系雄マウスを1群5匹
として、被検薬皮下投与30分後に0.6%酢酸
0.1ml/10gをマウスの腹腔内に注射し、そ
の後20分までに生ずるライシイング回数を数
えライシングを示さない場合を鎮痛効果陽性
と判定した。その結果を次に示す。 化合物 EDmg/Kg 実施例5 50ED20 〃 7 39ED50 4 抗炎症作用 体重110〜130gのウイスター系雄ラツトを使
用し、カラゲニンを足蹠浮腫法によつて本発明
化合物の抗炎症作用を調べた。その結果実施例
5の化合物は対照化合物フエニルブタゾンと同
等であり、実施例7の化合物は対照化合物より
強かつた。
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a phenylcyclohexane derivative represented by the following general formula (). (In the formula, R 1 is a hydrogen atom, a hydroxyl group or a methoxy group, R 2 is an N,N-dimethylaminoethyl group or an N,N-dimethylcarbamoylmethyl group, R 3 is a methylcarbonylamino group, (Ethylcarbonyloxy group, dimethylaminomethylcarbonyloxy group, dimelaminoethoxy group, or piperidinomethylcarbonyloxy group.) The compound of the present invention has an inhibitory effect on platelet aggregation, an inhibitory effect on isolated intestinal tract contraction, or an anti-inflammatory analgesic effect. It exhibits action and is useful as a medicine, and can be manufactured by the following general manufacturing method. Using 2-phenylcyclohexane or corresponding 2-phenylcyclohexanol represented by the following general formula () as a starting material, (However, when R 1 is a hydroxyl group, it is preferable to introduce a protecting group such as benzyl and finally remove the protecting group.) The compound of the present invention can be obtained by introducing R 2 and R 2 by a known method. Reference example 2-N,N-dimethylcarbamoylmethyl-2
-Production of phenylcyclohexanol 2-N,N-dimethylcarbamoylmethyl-2
- Phenylcyclohexanone 2.59g methanol
500mg of sodium borate under ice cooling in 50ml solution
After stirring at room temperature for 2 hours, the reaction solution was concentrated under reduced pressure, diluted with water, and extracted three times with ether. The extract was washed with water, dried, and concentrated under reduced pressure to obtain 2.6 g (yield
100%) crystals were obtained. The crystals were recrystallized from a benzene-hexane mixed solvent to obtain a pure product of the title compound. Melting point 112-113℃ IRνcm -1 : 3150 (OH), 1600 (CO) NMR: 2.50, 2.69 (-N-CH 3 ), 4.05 (-C H
-OH) Example 1 Production of 1-N,N-dimethylaminoethyl-2-propionyloxy-1-phenylcyclohexane 2.00 g (8.10 mmol) of 2-dimethylaminoethyl-2-phenylcyclohexanol was dissolved in 30 ml of methylene chloride. 0.774 ml (1.1 equivalent) of propionyl chloride and 0.945 g of sodium carbonate dissolved in
(1.1 equivalent) and heated under reflux for 2 hours. moreover
Add 0.704 ml (1 equivalent) of propionyl chloride and 0.859 g (1 equivalent) of sodium carbonate and mix at room temperature.
Stir for an hour. Pour the reaction solution into water, make alkaline with 10% ammonia solution, and extract with chloroform.
Chloroform layer 1 is extracted with a 2N aqueous hydrochloric acid solution. The aqueous layer is made alkaline with 10% ammonia solution and extracted with chloroform. The chloroform layer is dried and the solvent is evaporated to obtain an oil. 1 to 2 parts of chloroform
The chloroform layer extracted with normal hydrochloric acid aqueous solution was washed with 5% ammonia solution, the solvent was distilled off, and the layer was dissolved in ether. Extract with 2N hydrochloric acid aqueous solution and reduce the aqueous layer to 10%
After making alkaline with aqueous ammonia solution, extract with chloroform. The chloroform layer is dried and evaporated to give an oil. The oils are combined to give 2.08 g (72.5% yield) of the hydrochloride salt of the title compound. IRcm -1 : 1740 (CO) NMR: 0.71 (-CO-CH 2 -CH 3 ), 2.02 (-N
( CH3 ) 2 ), 5.18 (-CH--O--), 7.16 ( phenyl). Example 2 1-N,N-dimethylcarbamoylmethyl-2
-N,N-dimethylcarbamoyloxy-1-
Production of phenylcyclohexane 1.44 g (5.53 mmol) of 2-N,N-dimethylcarbamoylmethyl-2-phenylcyclohexanol (see reference example) was dissolved in anhydrous methylene chloride, and 590 mg (5.54 mmol) of anhydrous sodium carbonate was dissolved.
and 626 mg (5.53 mmol) of chloroacetyl chloride were added and heated under reflux for 2 hours. After cooling, the reaction solution was poured into water and extracted with methylene chloride (twice).
The extract was dried over anhydrous magnesium sulfate and concentrated under reduced pressure to obtain 1.86 g of chloroacetate of cyclohexanol (quantitative yield). Next, dissolve the above compound in benzene, put it in a sealed tube, and add a benzene solution containing 10 equivalents of dimethylamine.
Heated at 110 for 4 hours. The taken out benzene solution was washed twice with water, dried, and then concentrated under reduced pressure to obtain 1.35 g of the title compound (yield 71%). NMR: 2.27, 2.67 (-CO-N(CH 3 ) 2 ), 2.13
(-N(CH 3 ) 2 ), 2.90(-CO-CH 2 -N),
5.65 (-CH--O--CO) After converting it into a hydrochloride, it was recrystallized from an ethanol-ether mixed solvent to obtain a pure product. Melting point 77-79℃ Example 3 1-N,N-dimethylaminoethyl-2-N,
Production of N-dimethylcarbamoyloxy-1-phenylcyclohexane 4.32 g (17.5 mmol) of 2-dimethylaminoethyl-2-phenylcyclohexanol was dissolved in 120 ml of anhydrous benzene, and 1.39 ml of chloroacetyl chloride was dissolved at 5°C under a nitrogen stream. (1 equivalent) was added dropwise.
This was stirred at 5°C for 40 minutes. The solvent of the reaction solution was distilled off at 30°C to obtain an oily product of chloroacetate of cyclohexanol. Pour this into a sealed tube with a small amount of ethanol to make 100 ml of dimethylamine ethanol solution (15.2 equivalents containing about 12.0 g of dimethylamine).
Add and heat at 40-50℃ for 1 hour. The reaction solution was evaporated, suspended in water, and extracted with ether. The ether layer is extracted with a 2N aqueous hydrochloric acid solution, the aqueous layer is made alkaline with 10% aqueous ammonia, and extracted with methylene chloride. Dry the methylene chloride layer and evaporate the solvent to obtain 3.64 g of an oil. The oil was converted into a hydrochloride salt and recrystallized from ethanol-ether to obtain 1.60 g (yield 24.7%) of hydrochloride crystals of the title compound. Melting point 233-239℃ IRcm -1 : 1740 NMR: 2.07 (-N( CH3 ) 2 ) , 5.26 ( -CH-O- -), 7.23 (phenyl) Example 4 2-N-acetylamino-1 -Production of N,N-dimethylaminoethyl-1-phenylcyclohexane 2.12g (8.6 mmol) of 2-dimethylaminoethyl-2-phenylcyclohexanone was added to 20ml of
1.21 g (17.3 mmol) of hydroxylamine hydrochloride and 1.42 g (17.3 mmol) of hydroxylamine hydrochloride dissolved in 80% aqueous ethanol
(17.3 mmol) of anhydrous sodium acetate was added.
After heating under reflux for an hour, concentrate under reduced pressure. The residue was diluted with water, extracted three times with chloroform, and the extract was dried over anhydrous magnesium sulfate. The extract was filtered and concentrated under reduced pressure to obtain 2.25 g of crude product. IRνcm -1 : 1700 (C=N), 3300 (OH) This crude product was dissolved in 50 ml of anhydrous ether, this ether solution was added to a separately prepared ether solution containing excess lithium aluminum hydride, and the mixture was diluted with 2 Heat to reflux for an hour. After cooling the reaction mixture to 30%
Decompose with an aqueous caustic soda solution, extract three times with ether, wash the extract with saturated brine, and then dry over anhydrous magnesium sulfate. The dried extract was filtered and concentrated under reduced pressure to obtain 2.12 g of crude product. IRνcm -1 : 3500, 1640 (NH 2 ) The above crude product was dissolved in 20 ml of pyridine and acetic anhydride was added.
Add 10ml and stir at room temperature for 16 hours. The reaction solution was concentrated under reduced pressure, the residue was dissolved in methylene chloride, extracted with 2N hydrochloric acid, returned to basicity with 5% aqueous ammonia, and re-extracted three times with methylene chloride. After drying and concentrating under reduced pressure, 1.27 g of the title compound is obtained (yield: 60
%). IRνcm -1 : 1640 (CO), 3300 (NH) NMR: 1.60 (-COCH 3 ), 2.10 (-Z (CH 3 ) 2 ),
4.46 (-CH-NH--), 5.95 (-NH-CO-) The above compound was converted into a hydrochloride salt and then recrystallized from an ethanol-ether mixed solvent to obtain a pure product. Melting point 127-130℃ Example 5 1-N,N-dimethylcarbamoylmethyl-2
-N,N-dimethylcarbamoyloxy-1-
Preparation of (3-methoxyphenyl)cyclohexane 2.1 g (18.7 mmol) of potassium t-butoxide was dissolved in anhydrous dimethyl sulfoxide and 3.19
g (15.6 mmol) of 2-(3-methoxy)phenylcyclohexanone was added and stirred at room temperature for 30 minutes. Next, N,N-dimethylchloroacetamide
2.27 g (18.7 mmol) of dimethyl sulfoxide solution was added dropwise under ice cooling, and the mixture was heated and stirred at 100° C. for 2 hours. After cooling, the reaction solution was poured into water, extracted three times with chloroform, washed with water, and dried over anhydrous magnesium sulfate. When the extract is concentrated under reduced pressure after filtration,
5.86 g of crude product are obtained. 300g of this stuff
By performing column chromatography using silica gel, 1.75 g of pure 2-N,N-dimethylcarbamoylmethyl-2-(3-methoxy)phenylcyclohexanone was obtained (yield 39%). IRνcm -1 : 1700 (CO), 1640 (N-CO) NMR: 2.65, 2.79 (-N(CH 3 ) 2 ), 2.76 ( -CH 2 -CON- - ), 3.77 (-OCH 3 ) 1.75g The above compound was dissolved in methanol, sodium borohydride was added under ice cooling, and the mixture was stirred at room temperature for 2 hours, and then the reaction solution was concentrated. Water was added to the residue, and the product was extracted three times with ether, washed with water, and then dried over anhydrous magnesium sulfate. The extract was filtered and concentrated under reduced pressure to obtain 1.25 g of 2-N,N-dimethylcarbamoylmethyl-2-(3-methoxy)phenylcyclohexanol (yield 71%). IRνcm -1 : 3400 (OH), 1605 (N-CO) NMR: 2.60, 2.78 (N(CH 3 ) 2 ), 3.78 (O-
CH 3 ), 2.70 ( -CH- 2 -CON- - ), 4.1 ( -CH-OH -) 1.25 g (4.3 mmol) of the above compound was dissolved in methylene chloride, and 456 mg (4.3 mmol) of sodium carbonate and 456 mg (4.6 mmol) of chloroacetyl chloride are added and the mixture is heated to reflux for 2 hours. After cooling, the reaction mixture is poured into water and separated. The aqueous layer is extracted twice with methylene chloride, and both the methylene chloride layer and the previous methylene chloride layer are dried over anhydrous magnesium sulfate. After filtration, the residue was concentrated under reduced pressure to obtain 1.52 g of 2-N,N-dimethylcarbamoylmethyl-2-(3-methoxy)phenylcyclohexanol chloroacetate (yield 96%). A dimethylformamide solution containing 4.2 g of dimethylamine was added to a dimethylformamide solution of 1.52 g (4.3 mmol) of the above compound, and the solution was added in a sealed tube.
Heat at 100℃ for 4 hours. After cooling, the contents are poured into a flask and concentrated under reduced pressure. 2N hydrochloric acid and ether are added to the residue and separated. After adding 10% aqueous ammonia to the aqueous layer to make it salty, it was extracted three times with methylene chloride and dried over anhydrous magnesium sulfate. After filtration, the residue was concentrated under reduced pressure to obtain 1.35 g of the title compound (yield: 87%). NMR: 2.15 (-N(CH 3 ) 2 ), 2.30, 2.70 (-
CON(CH 3 ) 2 , 2.85 ( ―CH 2 ―CON― ‐ ), 2.95
(-CO-CH- 2 -N- -), 3.75 (-OCH 3 ),
5.65(-CH-O-CO-) After converting it into a hydrochloride, it was recrystallized from an ethanol-ether mixture to obtain a pure product. Melting point 191-192℃ Elemental analysis Molecular formula C 21 H 32 N 2 O 4・HCl Calculated value C: 61.08; H: 8.06; N: 6.78 Actual value C: 60.99; H: 8.14; N: 6.78 Example 6 1- N,N-dimethylcarbamoylmethyl-2
-N,N-dimethylcarbamoyloxy-1-
Production of (3-hydroxyphenyl)cyclohexane Potassium t- in 11 ml of anhydrous dimethyl sulfoxide
1.47 g (13.1 mmol) of butoxide was added little by little, then a dimethyl sulfoxide solution of 3.05 g (10.9 mmol) of 2-(3-benzylosi)phenylcyclohexanone was added, and after stirring at room temperature for 30 minutes, 2-chloro-N , N-dimethylacetamide
Add 1.59 g (13.1 mmol). Then the mixture
Heat and stir on a 100°C oil bath for 2 hours. After cooling, the reaction mixture was poured into water and extracted with methylene chloride (3
times). The extract was washed with water, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure to yield 4.2 g of 2-N,N.
-dimethylcarbamoylmethyl-2-(3-benzyloxy)phenylcyclohexanone is obtained. NMR: 2.59, 2.75(-N( CH3 ) 2 ) , 2.70( -CH2- CO-N--), 4.90(-O-C H2
-Phenyl) Dissolve 4.1 g (10 mmol) of the above compound in 50 ml of methanol, add 410 mg of equimolar sodium borohydride, and stir at room temperature for 1 hour. After concentration, it is diluted with water, extracted with methylene chloride, and the extract is washed with water and dried over anhydrous magnesium sulfate. After filtration and concentration under reduced pressure, 3.51 g of crude product is obtained. This product was separated and purified by silica gel column chromatography to obtain 2.0 g of 2-N,N-dimethylcarbamoylmethyl-2-(3-benzyloxy)phenylcyclohexanol (yield: 50% in two steps). . NMR: 2.55, 2.72(-N( CH3 ) 2 ), 2.65( -CH2 -CON--), 4.05(-CH-OH-),
5.04 (-O-CH- 2 -phenyl) 1.5 g (4.08 mmol) of the above compound was dissolved in 50 ml of methylene chloride, and an equimolar amount of soda carbonate (435 mg) was dissolved.
and chloroacetyl chloride (461 mg), and heated under reflux for 1.5 hours. After cooling, the reaction solution is poured into water, extracted with methylene chloride, and the extract is dried over anhydrous magnesium sulfate. 1.47g when concentrated under reduced pressure after filtration
2-N,N-dimethylcarbamoylmethyl-2-(3-benzyloxy)phenylcyclohexanol chloroacetate is obtained (yield:
81%). IRνcm -1 : 1620 (-CO-N), 1730 (-COO-) NMR: 2.60, 2.75 (-N(CH 3 ) 2 ), 3.76 (Cl-C
H 2 -COO), 5.01 (-O-C H 2 -phenyl),
5.59 (-CH--OCO-) Dimethylformamide containing 20 equivalents of dimethylamine is added to a solution of 1.36 g of the above compound in dimethylformamide and heated in a sealed tube at 100-110°C for 4 hours. When concentrated under reduced pressure, 1.22 g of 2-N,N-dimethylcarbamoylmethyl-2-(3-benzyloxy)phenylcyclohexanol, N,N-
Dimethylamino acetate is obtained (yield 88
%). IRcm -1 : 1620 (-N- CO ), 1720 (-O- CO -) NMR: 2.25, 2.67 (-CO-N(CH 3 ) 2 ), 2.15
(-CH 2 -N(CH 3 ) 2 ), 2.60 ( -CH 2 -CO-N- - ), 2.90 ( -CO-CH 2 -N- - ), 5.00 (-O-CH 2
-Phenyl) 1.21 g of the above compound was converted into a hydrochloride salt, dissolved in ethanol, and 1.2 g of 10% palladium carbon was added thereto, followed by stirring for 5 hours under a hydrogen stream. After filtration, it is concentrated and the residue is fractionated between 2N hydrochloric acid and ether. hydrochloric acid layer
After making basic with 10% aqueous ammonia, extract with chloroform and dry over anhydrous magnesium sulfate.
After filtration and concentration under reduced pressure, 820 mg of the title compound is obtained (yield 85%). IRcm -1 : 3300 (-OH), 1720 (-COO), 1640
(-N-CO) NMR: 2.20 (-N(CH 3 ) 2 ), 2.30, 2.72 (-CO
-N( CH3 ) 2 ), 2.55(-CH- 2 -CON--),
3.01 (-CO-CH- 2 -N--), 5.62 (-CH-O--) The above compound is converted into a hydrochloride salt and then recrystallized from an ethanol-ether mixed solvent to obtain a pure product. Melting point 144-145℃ Elemental analysis Molecular formula C 20 H 29 N 2 O 4 Calculated value C: 66.27; H: 8.34; N: 7.73 Actual value C: 66.50; H: 8.40; N: 7.73 Example 7 1-N, N-dimethylcarbamoylmethyl-1
-Production of (3-methoxyphenyl)-2-piperidinomethylcarbonyloxycyclohexane 1.14g of 2-N,N-dimethylacetamide-
Dissolve 2-(3-methoxy)phenylcyclohexanol chloroacetate in dimethylformamide, add 10 equivalents of piperidine, and heat and stir at 100°C for 4 hours. The reaction solution was concentrated and separated by adding 2N hydrochloric acid and ether. The aqueous layer was made basic by adding 10% aqueous ammonia, extracted three times with methylene chloride, and dried over anhydrous magnesium sulfate. After filtration, the mixture was concentrated under reduced pressure to obtain 1.19 g of the title compound as an oil (yield 97%). IRcm -1 : 1640 (-N-CO), 1730 (-OCOCH 2 ) NMR: 2.30, 2.70 (CON(CH 3 ) 2 ), 3.73 (-
OCH 3 ), 5.60 ( -CH - OCO -) This product was prepared as a hydrochloride. Elemental analysis As molecular formula C 24 H 3 N 2 O 4 Calculated value C: 69.20; H: 8.71; N: 6.73 Actual value C: 68.73; H: 8.86; N: 6.69 Example 8 2-N,N-dimethylaminoethyl Oxy-1
-N,N-dimethylcarbamoylmethyl-1-
Production of (3-methoxyphenyl)cyclohexane 2-N,N-dimethylacetamide-2-(3
-Methoxy)phenylcyclohexanol 700mg
(2.4 mmol) was dissolved in anhydrous dimethylformamide, added with sodium hydride under a nitrogen stream, and stirred at room temperature for 30 minutes. Next, dimethylaminoethyl chloride was added dropwise and stirred at room temperature for 1 hour, then heated to 50°C.
Heat and stir for an additional 2 hours. After cooling, the mixture was poured into water, extracted three times with methylene chloride, and then back-extracted with 2N hydrochloric acid. The aqueous layer is made basic with 10% aqueous ammonia, then re-extracted with methylene chloride and dried over anhydrous magnesium sulfate. After filtration, the mixture was concentrated under reduced pressure to obtain 260 mg of the title compound as an oil (yield 31%). IRcm -1 : 1620 (-CON-) NMR: 2.20 (-N(CH 3 ) 2 ), 2.35, 2.70 (-
CON( CH3 ) 2 ), 2.80(-CH- 2 -CO-N--),
3.0―3.6(-O-CH2 - CH2- N--), 3.73(-
OCH 3 ), 4.05 ( -NH――O- -) Elemental analysis As molecular formula C 12 H 34 N 2 O 3 Calculated value C: 69.58; H: 9.45; N: 7.73 Actual value C: 69.56; H: 9.46; N :7.50 Next, the pharmacological effects of the compounds of the present invention will be described. 1. Platelet aggregation inhibitory effect Blood is collected from the ear artery of a rabbit using sodium citrate as an anticoagulant. Platelet-rich plasma (PRP) and platelet-poor plasma (PPP) by centrifugation fractionation
get. The platelet count was adjusted to 400,000 mm3 .
PRP250μ with agrometer (manufactured by Rika Denki)
1 mmol of calcium chloride was added while incubating at 37°C. After 1 minute, add an appropriate amount of the test compound.
After another minute, 10 μmol of adenosine diphosphate (ADP), 38 μg/ml of collagen, or 0.3 mmol of arachidonic acid is added as a flocculant, and the change in light transmittance is measured using an analog meter. For the agglutination effect, the maximum agglutination of the control is set as 100, and the inhibition rate is calculated using the sample concentration that inhibits the aggregation by 50% (IC 50 μ
g/ml). The results are shown in the table below. [Table] 2 Inhibitory effect on isolated intestinal contraction Approximately 2 cm from a male guinea pig weighing 400 to 700 g
The ileum was removed and tested using the Magnus method. The ileum was suspended in a Magnus bath (Tyrode's solution 38°C with air aeration), and its contraction response was recorded via an isotonic transducer. After setting the intestinal tract to a constant length, add carbachol or histamine at 1×10 -10 to 1×
Within the concentration range of 10 -5 g/ml, after determining the dose-response curve for the contractile by adding it cumulatively, wash and determine the dose-response curve for the contractile in the presence of the test compound. Antagonism due to difference
PD 2 ′ was calculated. The results are shown below. Compound PD 2 ' Example 1 4.59 〃 2 4.06 〃 3 4.35 Control papaverine 5.43 3 Analgesic effect a Acetic acid ricing method (1) Test compound was orally administered for 30 minutes to groups of 5 ddY male mice weighing 15 to 20 g. 0.6% after
Inject 0.1ml/10g of acetic acid into the abdominal cavity of the mouse.
The number of ricings that occurred after 5 to 10 minutes was counted, and if the number of ricings was less than 10, it was determined that the analgesic effect was positive. The results are shown below. Compound ED 50 mg/Kg Example 1 32 〃 2 21 〃 3 65 〃 4 53 〃 5 3.9 b Acetic acid lysing method (2) Subcutaneous administration of test drug to groups of 5 ddY male mice weighing 16-20 g 0.6% acetic acid after 30 minutes
0.1 ml/10 g was intraperitoneally injected into the mouse, and the number of lysings occurring within 20 minutes thereafter was counted, and if no lysing was observed, it was determined that the analgesic effect was positive. The results are shown below. Compound EDmg/Kg Example 5 50ED 20 〃 7 39ED 50 4 Anti-inflammatory activity Using male Wistar rats weighing 110 to 130 g, the anti-inflammatory activity of the compounds of the present invention was investigated using carrageenan by the footpad edema method. As a result, the compound of Example 5 was equivalent to the control compound phenylbutazone, and the compound of Example 7 was stronger than the control compound.

Claims (1)

【特許請求の範囲】 1 下記一般式()で表わされるフエニルシク
ロヘキサン誘導体。 (式中、 R1は水素原子、水酸基またはメトキシ基のい
ずれか、 R2はN,N―ジメチルアミノエチル基または
N,N―ジメチルカルバモイルメチル基のいずれ
か、 R3はメチルカルボニルアミノ基、エチルカル
ボニルオキシ基、ジメチルアミノメチルカルボニ
ルオキシ基、ジメチルアミノエトキシ基またはピ
ペリジノメチルカルボニルオキシ基のいずれかを
示す。)
[Claims] 1. A phenylcyclohexane derivative represented by the following general formula (). (In the formula, R 1 is a hydrogen atom, a hydroxyl group or a methoxy group, R 2 is an N,N-dimethylaminoethyl group or an N,N-dimethylcarbamoylmethyl group, R 3 is a methylcarbonylamino group, Indicates either ethylcarbonyloxy group, dimethylaminomethylcarbonyloxy group, dimethylaminoethoxy group, or piperidinomethylcarbonyloxy group.)
JP56008493A 1981-01-21 1981-01-21 Phenylclohexane derivative Granted JPS57122041A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP56008493A JPS57122041A (en) 1981-01-21 1981-01-21 Phenylclohexane derivative
JP2073923A JPH02275871A (en) 1981-01-21 1990-03-23 Phenylcyclohexane derivative

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP56008493A JPS57122041A (en) 1981-01-21 1981-01-21 Phenylclohexane derivative

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2073923A Division JPH02275871A (en) 1981-01-21 1990-03-23 Phenylcyclohexane derivative

Publications (2)

Publication Number Publication Date
JPS57122041A JPS57122041A (en) 1982-07-29
JPH0250894B2 true JPH0250894B2 (en) 1990-11-05

Family

ID=11694637

Family Applications (1)

Application Number Title Priority Date Filing Date
JP56008493A Granted JPS57122041A (en) 1981-01-21 1981-01-21 Phenylclohexane derivative

Country Status (1)

Country Link
JP (1) JPS57122041A (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2571755Y2 (en) * 1992-04-24 1998-05-18 住鉱テック 株式会社 Flat cable connector
CN115108875B (en) * 2021-03-18 2023-07-04 河南师范大学 Nitrogen-containing heteroarene chiral cyclic alcohol constructed by asymmetric catalysis of visible light, and preparation method and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50157342A (en) * 1974-03-04 1975-12-19
JPS51138680A (en) * 1975-05-24 1976-11-30 Grelan Pharmaceut Co Ltd Process for preparing dibenzopyrans.
US4150135A (en) * 1974-09-09 1979-04-17 E. I. Du Pont De Nemours And Company Substituted 4a-phenyl-N-phenylalkyl-cis-decahydroisoquinolines

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50157342A (en) * 1974-03-04 1975-12-19
US4150135A (en) * 1974-09-09 1979-04-17 E. I. Du Pont De Nemours And Company Substituted 4a-phenyl-N-phenylalkyl-cis-decahydroisoquinolines
JPS51138680A (en) * 1975-05-24 1976-11-30 Grelan Pharmaceut Co Ltd Process for preparing dibenzopyrans.

Also Published As

Publication number Publication date
JPS57122041A (en) 1982-07-29

Similar Documents

Publication Publication Date Title
FR2640266A2 (en) DERIVATIVES OF (1-HYDROXY PIPERIDINYL-2 ALKYL) INDOLONES-2, QUINOLININES-2, BENZO (B) AZEPINONES-2 AND BENZIMIDAZOLONES-2, THEIR PREPARATION AND THEIR THERAPEUTIC USE
JPH0559096A (en) New amino steroid compound
AU698595B2 (en) 3-phenylisoquinol-1(2H)-one derivatives, their preparation and their therapeutic application
MAY et al. Structures related to morphine. III. Synthesis of an analog of N-methylmorphinan
JP2001505198A (en) Substituted dihydrobenzofurans as PDE inhibitors
JPS6013788A (en) Novel coumarin derivative
JPH06506442A (en) 1-(4-acylaminophenyl)-7,8-methylenedioxy-5H-2,3-benzo-diazepine derivatives and acid addition salts thereof, pharmaceutical compositions containing the same, and methods for producing the same
JPS6345282A (en) Rifamycin derivative having both acyl group and substituted alkyl group
CN108947946B (en) Brain injury resistant deuterated compound and medical application thereof
RAO et al. Synthesis of some steroidal nitrogen mustards
US3420834A (en) 2,3-dimethoxy-berbines substituted in the 10 position and process
JP3466527B2 (en) New aconitine compounds and analgesic / anti-inflammatory agents
CN112110897A (en) Preparation method of deuterated crizotinib and derivative thereof
JPH0250894B2 (en)
JPS5970681A (en) 5-substituted 2,3-dihydrobenzofuran-2-carboxylic acids and their derivatives
JPH07291974A (en) Epi-epibatidine derivative and its preparation
WO1995021827A1 (en) Novel aconitine-like compound and antipyretic analgesic anti-inflammatory agent
JPH085862B2 (en) Novel aconitine compounds and analgesic / anti-inflammatory agents containing them as active ingredients
JP2846418B2 (en) Naphthalene derivative
JP3471778B2 (en) Tricyclic fused heterocyclic compound, production method and use thereof
JP2007131558A (en) Acetoxychavicol acetate analog compound, its preparation method and antiallergic agent
Baltzly et al. Amines Related to 2, 5-Dimethoxyphenethylamine. 1 I
JP2748061B2 (en) Antitumor agent containing benzo [C] phenanthridinium derivative as active ingredient
JPS588379B2 (en) Para-isobutylhydroatrobic acid derivative and its production method
CA1248118A (en) Phenylacetic ester derivatives and process for preparing the same